NervGen Pharma to Advance New Drug Candidate Into Preclinical Proof-of-Concept Stage

NervGen Pharma (NGEN.V) was last seen up 5% after the company on Tuesday said it plans to develop a new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophi

MT NewswiresJun 25 13:18 ET

NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus

NervGen Pharma Corp. Price Target Announced at C$4.00/Share by Stifel Nicolaus

Dow JonesMay 1 12:01 ET

NervGen Pharma Closes C$23 Million Bought Deal Financing

NervGen Pharma Corp. (NGEN.V) said Thursday that it has raised gross proceeds of about C$23 million by completing its bought deal financing. This includes the full exercise of the underwriters' over-a

MT NewswiresMar 28 13:12 ET

NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units

NervGen Pharma (NGEN.V) on Thursday said it is raising it is raising C$20.1 million in a bought-deal offering of share units. The biotech company said it is selling an underwriting syndicate 8.52-mill

MT NewswiresMar 21 16:10 ET

NervGen Pharma Extends the Expiry Date of Certain Stock Options

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing i

newsfileJun 2, 2023 18:15 ET

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Yahoo FinanceJan 6, 2023 06:02 ET